Drug Development Partner
We are a trusted and renowned global drug development accelerator. Our unique and innovative approach to development extends beyond traditional CRO & CDMO outsourcing paradigms by providing an integrated platform that combines drug substance, formulation development, real-time adaptive manufacturing and clinical testing under one organization and a single program manager.
Quotient Sciences has over 30+ years of experience in small molecule drug substance synthesis and manufacturing, drug product formulation development, clinical trial manufacturing, commercial launch and supply as well as our unique Translational Pharmaceutics® drug accelerator platform.
We partner with emerging biotechnology and large pharmaceutical companies to develop the next generations of therapies that make a difference for those that need them the most.
Bringing together over a century of industry experience to your program, Quotient Sciences recently introduced a collaboration with Charles River who have deep expertise in medicinal chemistry, biology, DMPK, early pharmaceutics, and non-clinical safety. This, coupled with Quotient Sciences' expertise in drug substance synthesis, drug product development, manufacturing, and clinical testing creates a solution with a full set of deliverables to help get your molecule 'clinic ready', and improve your chances of clinical success.
From first-in-human testing to drug product supply for patient trials, explore our programs for accelerating candidate development, early development, and late development.
From formulation development through data sciences and drug development consulting, our services can be tailored to your individual needs.
Quotient Sciences has extensive knowledge and growing capabilities in oncology therapeutics, orphan and rare disease drug treatments, and pediatric formulation development.
These enable us to provide you with drug program solutions, fast. Together, we are driven by the strong belief that ideas need to become solutions, and molecules need to become cures, fast.
If you are looking to accelerate the development of your oncology drug candidate, we are your ideal partner. At Quotient Sciences we have worked on over 300 oncology development projects for 91 different oncology drug candidates spanning 34 different disease indications. Our experts are ready to discuss your oncology drug development today.
Throughout the world, there are over 300 milion people living with identified rare diseases. At Quotient Sciences we recognize that there is a clinical need to accelerate orphan drug development from candidate selection to commercial manufacture and supply. In the past fives years, we have developed over 50 rare disease programs, we understand their barriers and possess the expertise needed to get these programs to patients fast.
Driven by patient needs and regulatory requirements, Quotient Sciences has gained considerable knowledge and capabilities in palatable pediatric formulations and product development. This experience enables us to provide uniquely integrated pediatric drug development solutions.
With over 30 years of experience and a successful portfolio encompassing thousands of molecules across all stages of development, we can help address the most critical challenges in drug development. Contact us today to learn how we can help accelerate your program.